Sharps Technology INC 8-K filings

Sharps Technology is strategically positioned to benefit from recent FDA recalls and increased tariffs on Chinese-made syringes, according to a shareholder letter from the company's CEO.

Sharps Technology, Inc. has entered into a five-year purchase agreement with Nephron for a minimum of $188.5 million in syringes and amended its asset purchase agreement with InjectEZ, LLC.

Sharps Technology enters into a cooperative sales and distribution agreement with Roncadelle Operations s.r.l. and a logistics agreement with Owens & Minor, while terminating its previous distribution agreement with Nephron Pharmaceuticals.

Sharps Technology and Roncadelle Operations have partnered to expand the global reach of their innovative safety syringe product lines.

Sharps Technology has been granted a second 180-day extension, until July 8, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

Sharps Technology and Roncadelle Operations have signed a Letter of Intent to collaborate on sales and distribution, expanding their reach into new global markets.